Drug common name | Casopitant |
INN | casopitant |
Description | Casopitant (INNTooltip International Nonproprietary Name),: 208 former tentative trade names Rezonic (U.S.) and Zunrisa (Europe), is an NK1 receptor antagonist which was undergoing research for the treatment of chemotherapy-induced nausea and vomiting. It was under development by GlaxoSmithKline. In July 2008, the company filed a marketing authorisation application with the European Medicines Agency. The application was withdrawn and development was discontinued in September 2009 because GlaxoSmithKline decided that further safety assessment was necessary. However, a 2022 review listed casopitant as under development as a potential novel antidepressant for the treatment of major depressive disorder, with a phase 2 clinical trial having been completed.
|
Classification | Small molecule |
Drug class | tachykinin (neurokinin) receptor antagonists: NK1 receptor antagonists |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CC(=O)N1CCN([C@H]2CCN(C(=O)N(C)[C@H](C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)[C@@H](c3ccc(F)cc3C)C2)CC1 |
PDB | — |
CAS-ID | 414910-27-3 |
RxCUI | — |
ChEMBL ID | CHEMBL1672054 |
ChEBI ID | — |
PubChem CID | 23725089 |
DrugBank | — |
UNII ID | 3B03KPM27L (ChemIDplus, GSRS) |